Company Insights

MXCT customer relationships

Explore interactive graphBrowse insights index
MXCT customer relationship map

MaxCyte (MXCT) Customer Map: Platform Licensing, Strategic Partners, and Commercial Signals

MaxCyte monetizes a proprietary Flow Electroporation® platform by selling instruments, licensing its ExPERT systems for clinical use, and capturing recurring annual license fees plus consumables and services. Revenue is driven by a hybrid model: capital instrument sales, high‑value short‑term clinical licenses (typically $150k–$250k per instrument per year), and consumables/technical support that scale with customer throughput and clinical progression. This combination produces a recurring revenue backbone with high customer concentration and strong validation from large biopharma partnerships. For a deeper view of these customer relationships, visit https://nullexposure.com/.

How MaxCyte actually makes money and what that implies for investors

MaxCyte’s go‑to‑market is a licensed‑hardware model with follow‑on recurring economics. The company sells instruments and provides non‑exclusive research licenses for preclinical work, while retaining title and issuing clinical licenses for GMP production — a contractual posture that converts discrete sales into multi‑year revenue streams. Licensing is recognized ratably and often treated as a short‑term lease, meaning near‑term revenue visibility is tied to license terms and renewal cycles. The business is concentrated and enterprise‑facing: one customer represented 23% of revenue in 2024, and the installed base exceeds 760 instruments globally, giving MaxCyte a durable consumables and services revenue runway. Geography is global with a meaningful North American bias but active expansion across EMEA and APAC.

Customer and partner relationships: what the headlines say

Below are the customer relationships surfaced in public reporting and press coverage. Each entry is a plain‑English description and a concise source note.

PHC Corporation (PHCbi) — exclusive Japan distribution (FY2025)

PHCbi’s Biomedical Division signed an exclusive agreement to distribute MaxCyte’s ExPERT platform in Japan, a move that expands MaxCyte’s commercial footprint through an established medical device distribution channel. This was reported by BioSpectrum Asia in March 2026 on the PHCHD/PHCbi arrangement.

SciMed (Asia) — exclusive Singapore distribution (FY2025)

SciMed (Asia), a PHCHD subsidiary, launched the ExPERT platform in Singapore under an exclusive distribution agreement, enabling localized sales and support in a strategic APAC market. BioSpectrum Asia covered the Singapore launch in March 2026.

Adicet Bio, Inc. (ACET) — strategic platform license (FY2025/FY2026)

Adicet obtained non‑exclusive research, clinical and commercial rights to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform, validating the platform’s role in CAR‑T/engineered cell programs. This was documented in industry outlets including SelectScience and Technology Networks in March 2026.

Kamau Therapeutics — strategic platform license (FY2025)

MaxCyte entered a strategic platform license with Kamau Therapeutics to accelerate development of cell therapies for genetic diseases, signaling adoption by smaller, specialized biotech programs. News‑Medical referenced this partnership in its October industry roundup.

LG Chem Ltd. — strategic license for allogeneic CAR‑T (FY2022)

LG Chem secured non‑exclusive clinical and commercial rights to MaxCyte’s ExPERT platform to advance its allogeneic CAR‑T programs, providing enterprise validation from a major pharmaceutical conglomerate. Technology Networks reported this agreement and cited the licensing terms.

prime medicine (PRME) — strategic platform license (FY2025)

prime medicine entered a strategic platform license to advance next‑generation gene editing therapies, showing MaxCyte’s role in enabling high‑precision gene editing workflows. News‑Medical listed this in its October 2023 coverage of cell‑therapy advancements.

TG Therapeutics (TGTX) — platform usage (FY2025)

TG Therapeutics announced plans to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform, reflecting adoption by oncology/hematology drug developers for clinical‑stage cell manufacture. News‑Medical included TG Therapeutics in its industry roundup.

Vittoria Biotherapeutics — strategic platform license (FY2025)

Vittoria signed a strategic platform license with MaxCyte to advance next‑generation cellular therapies, another example of MaxCyte’s reach into focused cell‑therapy startups. This relationship was covered by News‑Medical.

Moonlight Bio — strategic platform license (FY2026)

MaxCyte executed a platform license agreement with Moonlight Bio to advance T‑cell therapies for solid tumors, highlighting use of the ExPERT platform in solid tumor immunotherapy initiatives; MarketScreener and FinViz carried reports in October 2025 and March 2026.

Beam Therapeutics (BEAM) — academic/industry research linkage (FY2025)

Researchers from Beam and academic centers used MaxCyte electroporation to deliver ABE8e mRNA in HSC editing studies for sickle cell disease, demonstrating MaxCyte’s utility in cutting‑edge gene‑editing experiments. Coverage appeared in The Scientist.

Lyell Immunopharma (LYEL) — strategic platform license (FY2025)

Lyell signed a strategic platform license with MaxCyte, further validating use of ExPERT in companies developing engineered T‑cell therapies; reported in industry press in late 2023 and summarized in News‑Medical.

Casdin Partners Master Fund, L.P. — participation in public offering (FY2021)

Casdin indicated interest in purchasing 1.8 million shares in an upsized offering, signaling institutional investor participation during MaxCyte’s public capital raises and supporting balance sheet expansion. This was disclosed via PR Newswire in 2021.

What the relationship map implies for revenues and risk

  • Recurring revenue engine: Clinical licensing terms (typical annual fees of ~$150k–$250k per instrument) create predictable, annuity‑style revenue when customers advance to clinical manufacture.
  • High spend band per customer: The company’s licensing model places customers in a $100k–$1m spend band per instrument annually, aligning incentives for consumables and support upsell.
  • Concentration and counterparty quality: The customer base includes large biopharma and government/academic institutions, producing strong validation but also concentration risk — one customer accounted for 23% of revenue in 2024.
  • Global but North‑America weighted: More than 760 instruments placed globally with ~33% revenue from international markets indicates scale but also reliance on a few key geographic markets.
  • Contract maturity and criticality: Many customers are active in clinical development (18 of the SPL customers had IND‑level activity), implying licenses are mission‑critical as programs approach commercialization.

For investors, track license renewals, the progression of SPL customers from IND to commercial stage, consumables attach rates, and regional distribution rollouts such as the PHC/SciMed APAC channel expansion. For tailored relationship intelligence and due diligence, visit https://nullexposure.com/ for in‑depth mapping.

Takeaway and next steps

MaxCyte’s revenue model is defensible and modular: instrument placements seed long‑term license and consumables revenue, while strategic licenses with established biopharma firms validate the platform at scale. Key risks are customer concentration and the timing of clinical milestones that drive renewals; these are offset by multiple large partner licenses and distribution agreements that broaden reach.

To explore the full customer network and diligence signals, go to https://nullexposure.com/. For an investor briefing or customized customer‑risk analysis, visit https://nullexposure.com/ and request a relationship map tailored to MXCT.